[Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
Dermal administration is a nonoral drug delivery system that can keep the concentration of a drug in the body at a proper level for a long time. This is suitable especially in patients in the advanced stages of Parkinson's disease with a wearing-off phenomenon (short duration of effects on antiparkinsonian drugs), or in postoperative patients who cannot be treated with oral administration. We studied the effects of lisuride, a dopamine receptor agonist, in the dermal application on MPTP-treated common marmosets and on 5 patients with Parkinson's disease. Lisuride was applied to 4 x 5 cm of skin of the abdomen of monkeys. In patients with Parkinson's disease, lisuride was applied to the skin of the chest. The agent reversed akinesia of MPTP-treated animals within 30 min following the application and relieved the animal of parkinsonism for 5 days at a dose of 2 mg/kg. In patients, the dermal application of lisuride increased the duration of the ON period at doses of 1 to 2 mg/kg. These results suggest that the dermal application of lisuride is a useful treatment in parkinsonism.
Nomoto
M
M
Department of Pharmacology, Kagoshima University School of Medicine, Japan.
Iwata
S
S
Irifune
M
M
Kaseda
S
S
Osame
M
M
Fukuda
T
T
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000279:Administration, Cutaneous; D000368:Aged; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002144:Callithrix; D002940:Circadian Rhythm; D004195:Disease Models, Animal; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008090:Lisuride / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000188:drug therapy / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008090:Lisuride